Modality switching between therapy and imaging based on the excitation wavelength dependence of dual-function agents in folic acid-conjugated graphene oxides

Seung Won Jun; Junyoung Kwon; Soo Kyung Chun; Hyun Ah Lee; Jaebeom Lee; Dae Youn Hwang; Chen-Yuan Dong; Chang-Seok Kim

doi:10.1364/BOE.9.000705

Modality switching between therapy and imaging based on the excitation wavelength dependence of dual-function agents in folic acid-conjugated graphene oxides

Biomed Opt Express. 2018 Jan 22;9(2):705-716. doi: 10.1364/BOE.9.000705. eCollection 2018 Feb 1.

Authors

Seung Won Jun^{1

2}, Junyoung Kwon^{1

2}, Soo Kyung Chun¹, Hyun Ah Lee³, Jaebeom Lee¹, Dae Youn Hwang³, Chen-Yuan Dong⁴, Chang-Seok Kim¹

Affiliations

¹ Department of Cogno-Mechatronics Engineering, Pusan National University, Busan 46241, South Korea.
² The first two authors contributed equally to this work.
³ Department of Biomaterials Science, Pusan National University, Miryang 50463, South Korea.
⁴ Department of Physics, National Taiwan University, Taipei 10617, Taiwan.

Abstract

Owing to its near infrared (NIR) absorption, graphene oxide (GO) is promising for both photothermal (PT) therapy and multiphoton (MP) imaging. Novel therapy/imaging modality switching is proposed here based on the selected excitation wavelength of femtosecond (FS) laser. GO-based destruction of cancer cells is demonstrated when the laser power of 800-nm-wavelength FS laser is increased above 7 mW. However, GO-based imaging is mainly monitored without damaging the sample when using 1200-nm wavelength FS laser in the same laser power range. Folic acid (FA) conjugated graphene oxide (FA-GO) was synthesized for selective cancer cell targeting. Dual-function FA-GO-based cancer cell targeting agents were experimentally optimized to enable therapy/imaging modality switching.

Keywords: (110.0180) Microscopy; (160.4236) Nanomaterials; (170.0170) Medical optics and biotechnology; (180.4315) Nonlinear microscopy; (190.4180) Multiphoton processes; (190.4870) Photothermal effects.